San Diego – July 7, 2016 – Cooley advised Flexion Therapeutics on its follow-on offering of 5,500,000 shares of common stock for gross proceeds of $77 million.
Flexion, which trades on The NASDAQ Global Market, is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, or OA, a type of degenerative arthritis.
Cooley advised Flexion on its IPO in February 2014 and its subsequent follow-on offering in December 2014.
The Cooley corporate and securities team advising Flexion included Tom Coll, Sean Clayton, Nicole van de Leuv, Terren O'Connor, Andrew Harline and Edmond Lay.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.